| Our findings highlight that depression is associated with an increased risk for complications in type 2 diabetes and mortality and should not be neglected (Acta Diabetologica)
Our results suggest that accumulation of BM proteins is a general phenomenon in the medial layer of non-atherosclerotic arteries in patients with T2DM. Moreover, we identify additional T2DM-associated effects on the arterial proteome, which requires validation in future studies (Cardiovascular Diabetology)
Glycemic values in people with T1D significantly improved during COVID-19 lockdown, which may be associated with positive changes in self-care and digital diabetes management. In contrast, lockdown rather determined a short-term worsening in glycemic parameters in patients with T2D (Diabetology & Metabolic Syndrome)
Treatment with SGLT2 inhibitors improves liver structure and function in patients with T2D. This meta-analysis suggests that SGLT2 inhibitors are a promising pharmacological approach for treatment of NAFLD (Diabetes/Metabolism Research and Reviews)
This study introduces a dynamic and non-invasive assessment strategy for the underlying pathogenesis of diabetic peripheral neuropathy (Diabetologia)
In patients with type 2 diabetes and preserved renal function treatment with M+I resulted in reduction of renal perfusion and increase in vascular resistance, in contrast to treatment with E+I that preserved renal perfusion and reduced vascular resistance (Cardiovascular Diabetology)
You can now review and comment on this draft guideline (NICE)
You can now review and comment on this draft guideline (NICE)
We have identified subtle (nonpathological) changes in neonatal metabolism that represent a signature effect of fetal metformin exposure (Diabetes Care)
In patients with type 2 diabetes and cardiovascular disease, empagliflozin markedly and durably delays insulin initiation and substantial increases in insulin dose while facilitating sustained reductions in insulin requirements over time (Diabetes, Obesity and Metabolism)
The SDgluc is a significant independent contributor to subclinical diabetic polyneuropathy, in addition to conventional risk factors including diabetes duration and HbA1c (Journal of Diabetes Investigation)
| 